Anti-Ro and anti-La seropositivity is associated with increased rates of ischemic heart disease in adults- results from a large population-based study.

Background and aims Emerging evidence suggests an arrhythmogenic effect of Anti-Ro/SSA (anti-Ro) and anti-La/SSB (anti-La) antibodies in adults, potentially involving a subclinical intracardiac inflammatory process. Despite the established association between inflammation and ischemic heart disease (IHD), it is noteworthy that as of now no study has delved into the potential link between these antibodies and IHD. This population-based study aimed to examine the association between anti-Ro/La seropositivity and IHD in the general adult population. Methods We conducted a retrospective study using electronic medical records from the largest health maintenance organization in Israel. Patients with positive serology for either or both anti-Ro and anti-La antibodies were included, along with matched controls. Multivariate logistic regression models were utilized to assess the odds of IHD in seropositive patients compared to controls. Results Among 17,231 seropositive patients and 84,368 controls, the rate of IHD was significantly higher in the seropositive group (9.7% vs. 8.1%,OR=1.23; 95%CI 1.14-1.31; p<0.001). The association was more pronounced in younger patients [<40 years old(OR=3.36; 95%CI 1.66-6.82;p<0.001), 40-49 years old(OR=1.85; 95%CI 1.26 -2.73;p<0.01), 50-59 years old(OR=1.87; 95%CI 1.55-2.26; p<0.001), 60-69 years old(OR=1.26; 95%CI 1.11-1.42; p<0.001), ≥ 70 years old(OR=1.11; 95%CI 1.03-1.20;p<0.01)]. As well as in patients with fewer traditional cardiovascular risk-factors (none:OR=1.29; 95% CI 1.09 to 1.77;p<0.01, 1-2:OR=1.30; 95% CI 1.19 to 1.41;p<0.001, ≥3:OR=1.09; 95% CI 0.99 to 1.21;p=0.076). Conclusions Our study demonstrates for the first time a positive association between anti-Ro/La seropositivity and IHD in the general adult population, especially among younger individuals with fewer traditional cardiovascular risk factors.